Neurogene (NGNE) Total Current Liabilities (2013 - 2026)

Neurogene has reported Total Current Liabilities for 14 years, with the latest figure at $18.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 33.86% year-over-year to $18.9 million; the trailing twelve-month figure through Mar 2026 stood at $18.9 million (up 33.86% YoY), and the FY2025 full-year result was $16.4 million, up 8.27% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $18.9 million, up from $16.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $23.0 million in Q4 2023, with the low at $4.9 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $12.3 million across 5 years, with a median of $13.1 million in 2024.
• The largest YoY upside for Total Current Liabilities was 245.41% in 2023 against a maximum downside of 49.09% in 2023.
• Neurogene's Total Current Liabilities stood at $6.7 million in 2022, then surged by 245.41% to $23.0 million in 2023, then plunged by 34.02% to $15.2 million in 2024, then advanced by 8.27% to $16.4 million in 2025, then rose by 14.96% to $18.9 million in 2026.
• The last three Total Current Liabilities figures came in at $18.9 million (Q1 2026), $16.4 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.